Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:IPXL

Impax Laboratories (IPXL) Stock Price, News & Analysis

Impax Laboratories logo

About Impax Laboratories Stock (NASDAQ:IPXL)

Key Stats

Today's Range
$17.40
$18.95
50-Day Range
$18.30
$18.30
52-Week Range
$13.05
$25.70
Volume
3.04 million shs
Average Volume
945,265 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Receive IPXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Impax Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IPXL Stock News Headlines

Impax Global Environmental Markets Fd;Inv
Impax Large Cap Fund Individual Investor
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Impax International Sust Econ Instl
Impax US Sustainable Economy A
Impax Global Opportunities Institutional
Impax Sustainable Allocation Inv
Impax Sustainable Allocation Instl
See More Headlines

IPXL Stock Analysis - Frequently Asked Questions

Impax Laboratories, Inc. (NASDAQ:IPXL) announced its quarterly earnings results on Thursday, November, 9th. The specialty pharmaceutical company reported $0.23 EPS for the quarter, beating analysts' consensus estimates of $0.20 by $0.03. Impax Laboratories's quarterly revenue was down 9.4% on a year-over-year basis.

Based on aggregate information from My MarketBeat watchlists, some other companies that Impax Laboratories investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NovoCure (NVCR), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC) and Summit Midstream Partners (SMLP).

Company Calendar

Last Earnings
11/09/2017
Today
12/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:IPXL
CUSIP
45256B10
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:IPXL) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners